Triple-drug attack shows promise for inoperable liver cancer
NCT ID NCT07081633
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tests a combination of three drugs (durvalumab, tremelimumab, and lenvatinib) as the first treatment for people with advanced liver cancer that cannot be removed by surgery. About 114 participants will receive the drugs to see if they can slow cancer growth and improve survival. The goal is to control the disease, not cure it, and participants will need ongoing monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100029, China
-
Research Site
Beijing, 100044, China
-
Research Site
Beijing, 100142, China
-
Research Site
Chengdu, 610078, China
-
Research Site
Chongqing, 400016, China
-
Research Site
Guangzhou, 510060, China
-
Research Site
Guangzhou, 510095, China
-
Research Site
Guangzhou, 510120, China
-
Research Site
Guangzhou, 510515, China
-
Research Site
Hangzhou, 310022, China
-
Research Site
Hefei, 230022, China
-
Research Site
Jinan, 250021, China
-
Research Site
Nanjing, 210009, China
-
Research Site
Nanjing, 210029, China
-
Research Site
Ningbo, 315010, China
-
Research Site
Shanghai, 200032, China
-
Research Site
Shanghai, 200438, China
-
Research Site
Tianjin, 300060, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430030, China
-
Research Site
Xiamen, 361004, China
-
Research Site
Zhengzhou, 450052, China
-
Research Site
New Territories, Hong Kong
Conditions
Explore the condition pages connected to this study.